Developing improved therapeutic uses for existing molecules
Fully Integrated Specialty Pharmaceutical Company
Medexus Pharma, Inc. is a fully integrated specialty pharmaceutical company based in Chicago, Illinois. Medexus has core capabilities in development, operations and commercialization and is focused on the development and commercialization of treatments for autoimmune diseases, oncology, and other near market opportunities with the potential to impact patients’ lives. By forming new partnerships and leveraging our business development efforts, we have the opportunity to make significant medical advancements that can help patients live better lives.
Medexus Pharma, Inc., founded in 2012, is a wholly owned subsidiary of Medexus Pharmaceuticals, a Canadian-based pharmaceutical company formed in October 2018 through a transformative acquisition involving Pediapharm and Medexus, Inc. By combining Pediapharm’s Canadian pediatric specialty pharmaceutical business with the Canadian diversified specialty pharmaceutical business of Medexus and the U.S. autoimmune specialty pharmaceutical business of Medexus Pharma, the Acquisition creates a leading North American commercial-stage specialty pharmaceutical company strategically positioned for future growth.
Seasoned professionals with an entrepreneurial spirit
Our leadership team is composed of senior pharmaceutical and biotechnology professionals who have extensive experience in development, operations, sales, marketing, and commercialization. At Medexus Pharma, Inc. everyone can learn from some of the brightest minds in the industry while applying their own knowledge, skills, and expertise in a collaborative and supportive environment.
Personalized approach to medicine
Our team is dedicated to developing and commercializing medicines that offer the highest possible degree of safety and tolerability. We develop mid-to-late stage molecules as well as new drug dosage forms, concentrations, and modes of delivery that can potentially improve the safety profile, bioavailability, tolerability, and efficacy of existing medications, leading to better patient compliance and improved patient outcomes. We believe in taking a personalized approach to medicine, where patients have access to the best treatment options and the ability to manage their own therapy.
Practicing a patient-first philosophy
Patients are our priority
Our mission is to develop and deliver products and services that focus on improving health outcomes and quality of life.
We bring unique experiences and expertise to the table, but we all share a set of values that define our company culture.
- Be courageous.
- Be ethical.
- Be respectful.
- Be optimistic.
- Be passionate.
- Be collaborative.
- Be committed.
Engaging experience, expertise and entrepreneurship
Medexus Pharma’s management is comprised of a seasoned team of senior pharmaceutical and biotechnology professionals with extensive operational, sales, marketing, commercialization, and development expertise.
President & CEO
Terri Shoemaker founded Medac Pharma in June 2012 and served as President and Chief Executive Officer and a member of our the board of directors. Medac Pharma was acquired by Medexus Pharmaceuticals in October 2018. Since developing the business plan that led to a shareholder decision to launch the organization, Ms Shoemaker has implemented an ambitious commercial strategy in support of their commercial product for the treatment of rheumatoid arthritis.
Prior to joining Medexus Pharma, Ms. Shoemaker served as Vice President of Sales at InterMune where she developed a large-scale commercial sales infrastructure in preparation for the launch of a treatment for idiopathic pulmonary fibrosis. Before joining InterMune in 2009, Ms. Shoemaker co-founded BioPharm Strategic Solutions, providing commercial, operational and strategic guidance for start-up pharmaceutical and biotechnology organizations. In 2002 Ms. Shoemaker joined Pharmion Corporation, serving as National Sales Director and then Sr. Director US Commercial Operations building and leading a specialty oncology organization. In 2008 when Celgene Corporation acquired Pharmion, Ms. Shoemaker remained as Executive Director of Strategic Commercial Operations working as part of the executive transition team charged with building the new and fully aligned commercial organization. Ms. Shoemaker began her career at DuPont Pharmaceuticals, which was acquired by Bristol Myers Squibb in 2000, where she held a number of leadership positions including Senior Director of Sales, Director of Clinical Development & Education, and Director Marketing and Health Management.
Ms. Shoemaker holds B.S. degrees in Communication Science and Psychology from Missouri State University, and a M.S. degree in Communication Science and Disorders from University of Central Missouri.
Senior Vice President of Commercial Operations
Bill Poncy is currently Senior Vice President of Commercial Operations. His scope of responsibility includes trade, marketing, operations, distribution, and manufacturing.
Prior to joining Medexus Pharma, Mr. Poncy served as Vice President of Commercial Development at Accera, Inc., where he successfully developed and executed an integrated commercial plan for the Alzheimer’s disease treatment Axona. Before joining Accera, Mr. Poncy held the role of Vice President of Sales and Marketing at Myogen, Inc., leading the U.S. commercial effort and developing and implementing pre-launch and launch plans for all Myogen products. In 2001 Mr. Poncy joined Pharmion Corporation as Vice President of Sales and Marketing where he launched a specialty pharmaceutical commercial organization and served as a key member of the corporate management team. In 2000, Mr. Poncy served as Senior Director of National Sales. and then Senior Director of Marketing for Maxim Pharmaceuticals where he was responsible for building brand equity for Maxim’s Phase III oncology products. Mr. Poncy began his career at Berlex Laboratories as a sales representative, and then spent 16 years at DuPont where he served as Director of Integrated Healthcare, Director of National Accounts and Trade Relations, and Director of State Government Affairs.
Mr. Poncy holds a B.S. in Biological Sciences from the University of California at Irvine and an MBA from the University of Phoenix.
Vice President, Sales and Marketing
Brian Peters was appointed Vice President, Sales and Marketing in April 2018. Mr. Peters joined Medexus Pharma, Inc. in 2013 as Senior Director, Marketing, starting and building the Marketing function and overseeing marketing activities for the launch of Rasuvo®. Mr. Peters has over 28 years of strategic pharmaceutical commercial experience.
Before joining Medexus Pharma, Mr. Peters was Director, Marketing at Cornerstone Therapeutics, where he had responsibility for strategic product marketing and Marketing Operations. Prior to that, Mr. Peters held various senior level marketing positions at Accera, Gilead Sciences and GD Searle. Previously, he also held positions with the healthcare marketing agencies Klemtner, KPR and MedThink.
Mr. Peters holds a B.A. in Communications from Indiana University.
Vice President, Information Technology
Glenn Tate was appointed Vice President, Information Technology in October 2017. Mr. Tate joined Medexus Pharma, Inc. in 2014 as Senior Director, Information Technology. He built the technology functions to support the launch of commercial products and is responsible for managing the information technology department.
Prior to joining Medexus Pharma, he served as Director of Information Technology for Accera, Inc. where he built the information technology department and assisted in the launch of a commercial product. Previously, he was Director of Information Technology for Pharmion Corporation, where he built a technology team and assisted in the research, clinical trials, and global launches of multiple pharmaceutical products.
Mr. Tate started his career by holding in a multitude of technical roles including, support, engineering, and architecture for NeXagen, NeXstar Pharmaceuticals, and Gilead Sciences.
Mr. Tate holds a B.S. in Computer Science from Regis University.
Adhering to the Highest Ethical Standards
Medexus Pharma, Inc. is committed to creating a culture that encourages responsible corporate action at every level of our organization. We strive for the highest standards of business conduct and ethics.
Our Code of Conduct and Business Ethics illustrates the guiding ethical principles that support our commitment to compliance. Every day, we are faced with decisions and actions that give us the opportunity to embody the principles of our Code of Conduct. We are committed to maintaining an effective Compliance Program in accordance with federal and state government laws, regulations, and guidelines. We continually develop and implement policies, programs, and training activities to shape behaviors and help us achieve our compliance goals.
As part of the Medexus Pharma, Inc. continuing commitment to corporate compliance, Medexus Pharma, Inc. declares that, to the best of its knowledge, and based on a good faith understanding of the statutory requirements of California Health and Safety Code § 119400 and 119402, it has adopted a Comprehensive Compliance Policy as mandated by this California law. To the best of our knowledge, as of October 16, 2013, Medexus Pharma, Inc. is in substantial compliance with its Comprehensive Compliance Policy and its good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402.
For a copy of our Comprehensive Compliance Policy, you may request a copy via our contact us form or by calling 1-855-336-3322.